Germany - medicaments

Description

The Kaufmännische Krankenkasse - KKH (hereinafter referred to as KKH) pursues the goal of concluding discount agreements with all suitable pharmaceutical companies pursuant to Section 130a (8) SGB V for the following active ingredients and, if applicable, pharmaceutical forms within the framework of a so-called "open house procedure": Colecalciferol 20,000 I.E. / only WKA (ATC:A11CC05)Budesonide only NAS/ NDS (ATC:R01AD05)Budesonide only DOS (ATC:R03BA02)Xylometazoline (ATC:R01AA07)Loperamide (ATC:A07DA03)Iodide (ATC:H03CA01)Baclofen only INF (ATC:M03BX01)Buprenorphine only PFT (ATC:N02AE01)Zoledronic acid - 5mg (ATC:M05BA08)Paricalcitol only WKA (ATC:H05BX02)Dorzolamide only ATR in EDO (ATC:S01EC03)Methylphenidate HVW only (ATC:N06BA04)Octreotide ILO H01CB02On the basis of uniform contractual terms and conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies will be notified of the conclusion or the granting of a license to use the product. accession to a discount agreement pursuant to § 130a (8) SGB V for the above-mentioned active substance. Interested pharmaceutical companies can request the participation documents and the contract at the contact address given under l.1. At the same time as the contractual documents are requested, proof must be provided that the pharmaceutical company holds the relevant marketing authorisations for medicinal products containing the above active substance. Proof can be provided, for example, by means of a corresponding extract from the AMIS database. A prerequisite for the conclusion of a contract is that the interested pharmaceutical company completes and signs the required participation documents. A contract is concluded with every pharmaceutical company that fulfils the conditions for participation. Exclusivity is not given. The accession and/or the conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations will not be carried out. The earliest contract start date is 1.4.2019. If KKH carries out an invitation to tender for exclusive contracts in the form of the open procedure for the active substances during the contract term, the contracts concluded within the scope of this publication will be terminated in accordance with the contractual regulations. This publication does not constitute the award of a public contract within the meaning of the Public Procurement Coordination Directive between public procurement law and public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, publication shall take place in the Supplement to the Official Journal of the European Union. In the absence of an appropriate publication form, the contract notice shall be used. The resulting conceptual requirements, such as the designation of the procedure "open procedure", are owed solely to the use of this announcement form and the publication platform. This does not imply any further significance, in particular submission to subcontracting regulations, unless they are obligated for legal reasons.

Opportunity closing date

31 December 2020

Value of contract

to be confirmed